Herceptin

Herceptin shows biosimilar markets can work. To what extent is the question.
Herceptin shows biosimilar markets can work. To what extent is the question.
Medical Marketing and Media
Herceptin
biosimilars
Flag link:
Study: Biosimilars ‘fulfilling their promise’ of lowering biologic prices
Study: Biosimilars ‘fulfilling their promise’ of lowering biologic prices
BioSpace
biosimilars
biologics
drug pricing
Roche
Herceptin
Amgen
Kanjinti
Viatris
Ogivri
Pfizer
Trazimera
Teva Pharmaceutical
Herzuma
Organon
Ontruzant
Flag link:
Merck's Blockbuster Cancer Antibody Racks Up Another Approval
Merck's Blockbuster Cancer Antibody Racks Up Another Approval
BioSpace
Merck
Keytruda
FDA
Herceptin
gastric adenocarcinoma
Flag link:
AZ/Daiichi Sankyo’s Enhertu gets second US cancer indication
AZ/Daiichi Sankyo’s Enhertu gets second US cancer indication
Pharmaforum
AstraZeneca
Daiichi Sankyo
stomach cancer
Enhertu
Roche
Herceptin
Flag link:
MacroGenics wins FDA approval of breast cancer drug
MacroGenics wins FDA approval of breast cancer drug
BioPharma Dive
Margenza
Macrogenics
FDA
breast cancer
Roche
Herceptin
Flag link:
Merck launches Herceptin biosimilar in U.S.
Merck launches Herceptin biosimilar in U.S.
Seeking Alpha
Merck
Herceptin
Roche
biosimilar
Ontruzant
Flag link:
Pfizer launches biosimilars to Roche’s ‘big three’ cancer drugs in US
Pfizer launches biosimilars to Roche’s ‘big three’ cancer drugs in US
Pharmaforum
Pfizer
Roche
biosimilars
Avastin
Zirabev
Herceptin
Trazimera
Rituxan
Ruxience
Flag link:
WHO Prequalifies its First Biosimilar
WHO Prequalifies its First Biosimilar
RAPS.org
WHO
biosimilars
Samsung Bioepis
Ontruzant
Roche
Herceptin
breast cancer
Flag link:
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Pharmaceutical Business Review
Roche
Perjeta
Herceptin
HER2+ breast cancer
SABCS
breast cancer
Flag link:
SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis
SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis
Fierce Pharma
Roche
breast cancer
Herceptin
Perjeta
biosimilars
SABCS
Flag link:
Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio
Roche under fire again: Mylan launches Herceptin copycat in latest blow to blockbuster trio
Fierce Pharma
Roche
Mylan
Herceptin
biosimilar
cancer
oncology
Ogivri
Flag link:
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates
Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates
Pharmaforum
Daiichi Sankyo
Seattle Genetics
breast cancer
AstraZeneca
trastuzumab deruxtecan
Herceptin
Flag link:
SITC 2019 preview – Pieris joins the quest for a better Herceptin
SITC 2019 preview – Pieris joins the quest for a better Herceptin
EP Vantage
SITC
Pieris
Herceptin
PRS-343
Flag link:
As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo
As ‘big three’ oncology meds lose sales, Roche looks to file subcutaneous breast cancer combo
Pharmaforum
Roche
Perjeta
Herceptin
Genentech
HER2-positive breast cancer
Flag link:
Amgen biosimilar debut boosted by UnitedHealthcare coverage switch
Amgen biosimilar debut boosted by UnitedHealthcare coverage switch
Biopharma Dive
insurers
Amgen
biosimilars
Avastin
Herceptin
Roche
UnitedHealthcare
Flag link:
Roche doomsday is here: Long-feared Herceptin, Avastin biosims bust into U.S. market
Roche doomsday is here: Long-feared Herceptin, Avastin biosims bust into U.S. market
Fierce Pharma
Herceptin
Avastin
Roche
biosimilars
Allergan
Amgen
Flag link:
FDA Approves 20th Biosimilar, 5th for Roche’s Herceptin
FDA Approves 20th Biosimilar, 5th for Roche’s Herceptin
RAPS.org
FDA
biosimilars
Roche
Herceptin
Amgen
Kanjinti
Flag link:
Pfizer gets FDA approval for oncology biosimilar Trazimera
Pfizer gets FDA approval for oncology biosimilar Trazimera
Pharmaceutical Business Review
Pfizer
FDA
Trazimera
Genentech
biosimilars
Herceptin
Flag link:
Top 10 drugs losing exclusivity in 2019
Top 10 drugs losing exclusivity in 2019
Fierce Pharma
market exclusivity
patents
Rituxan
Lyrica
Herceptin
Avastin
Epclusa
Harvoni
Pfizer
Roche
Gilead Sciences
Amgen
GSK
Allergan
Individor
Flag link:
Roche wins US approval of more convenient Herceptin
Roche wins US approval of more convenient Herceptin
Biopharma Dive
Roche
Herceptin
breast cancer
Flag link:

Pages